Modification of valsartan drug release by incorporation into sericin/alginate blend using experimental design methodology

Autor(es)

Santinon, Caroline ^[1] ; de Freitas, Emanuelle Dantas ^[1] ; Carlos da Silva, Meuris Gurgel ^[1] ; Adeodato Vieira, Melissa Gurgel ^[1]

Afiliação do(s) autor(es)

^[1] Univ Campinas UNICAMP, Sch Chem Engn, Dept Proc & Prod Design, Albert Einstein Ave 500, BR-13083852 Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: EUROPEAN POLYMER JOURNAL; v. 153, JUN 15 2021.
• Citações Web of Science: 0

Resumo

Modifying pharmaceutical forms already available on the market is a strategy used by the pharmaceutical industries for optimizing the performance of different drugs. In the present study, a blend of sericin and alginate was proposed as a polymeric matrix for the incorporation of valsartan drug in order to prolong the release and maintain a more uniform concentration at patient's organism, reducing the chance of side effects. A 2 full-factorial design was carried out aiming the evaluation of the variables involved and optimizing the process. The formulations that contained lower content of incorporated drug obtained less satisfactory results of incorporation efficiency, although these formulations had shown longer in vitro release profiles. Analytical characterization techniques confirmed the incorporation of the drug into the matrix and showed an increase in the thermal stability of the drug after its incorporation into the polymeric matrix. Accelerated stability study proved the stability of the pharmaceutical form after 6 months period. (AU)

• Processo FAPESP: 16/05007-1 - Remoção de fármacos residuais em solução aquosa por adsorventes alternativos
• Beneficiário: Meuris Gurgel Carlos da Silva
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 15/13505-9 - Incorporação e liberação de fármacos em micropartículas de sericina e alginato
• Beneficiário: Melissa Gurgel Adeodato Vieira
• Modalidade de apoio: Auxílio à Pesquisa - Regular